Daily versus weekly azithromycin in cystic fibrosis patients

European Respiratory Journal

Volumn 30, Issue 3, 2007, Pages 487-495

  McCormack, J ^a,b   Bell, S ^b   Senini, S ^a   Walmsley, K ^a   Patel, K ^a   Wainwright, C ^b   Serisier, D ^b   Harris, M ^b   Bowler, S ^b  

^a Mater Adult Hospital

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Azithromycin; Cystic fibrosis; Macrolides; Pseudomonas aeruginosa

Indexed keywords

AZITHROMYCIN; C REACTIVE PROTEIN; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NUTRITION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; TREATMENT OUTCOME; BACTERIAL PNEUMONIA; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; FOLLOW UP; MIDDLE AGED; OPPORTUNISTIC INFECTION; VITAL CAPACITY;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PNEUMONIA, BACTERIAL; VITAL CAPACITY;

EID: 38449096089     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00163306     Document Type: Article

References (19)

1. Kudoh S, Uetake T, Hagiwara K, et al. [Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis.] Nihon Kyobu Shikkan Gakkai Zasshi 1987; 25: 632-642.
2. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57: 212-216.
3. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo controlled crossover trial. Lancet 2002; 360: 978-984.
4. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290: 1749-1756.
5. Clement A, Tamalet A, Le Roux E, Ravilly S, Fauroux B, Jais J-P. Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax 2006; 61: 895-902.
6. Albrich WC, Monnet DL, Harbarth S. Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes. Emerg Infect Dis 2004; 10: 514-517.
7. Phaff SJ, Tiddens HA, Verbrugh HA, Ott A. Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis. J Antimicrob Chemother 2006; 57: 741-746.
8. Amsden GW, Gray CL. Serum and WBC pharmacokinetics of 1500 mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers. J Antimicrob Chemother 2001; 47: 61-66.
9. Wildfeuer A, Laufen H, Zimmermann T. Distribution of orally administered azithromycin in various blood compartments. Int J Clin Pharmacol Ther 1994; 32: 356-360.
10. Scaglione F, Rossoni G. Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J Antimicrob Chemother 1998; 41: Suppl. B, 47-50.
11. Wilms EB, Touw DJ, Heijerman HGM. Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis. Ther Drug Monit 2006; 28: 219-225.
12. Bell SC, Senini SL, McCormack JG. Macrolides in cystic fibrosis. Chron Respir Dis 2005; 2: 85-98.
13. Gore CJ, Crockett AJ, Pederson DG, Booth ML, Bauman A, Owen N. Spirometric standards for healthy adult lifetime nonsmokers in Australia. Eur Respir J 1995; 8: 773-781.
14. Spirxpert. Become an expert in spirometry. www.spirxpert.com/pivotal2.htm Date last updated: January 2007. Date last accessed: June 29, 2007.
15. American Thoracic Society. ATS statement: Snowbird workshop on standardization of spirometry. Am Rev Respir Dis 1979; 119: 831-838.
16. Miller MB, Gilligan PH. Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis. J Clin Microbiol 2003; 41: 4009-4015.
17. Clinical Laboratory Standards Institute. Performance standards for antimicrobial sensitivity testing. 16th Informational Supplement 2006; 26: M100-S16.
18. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996; 335: 392-398.
19. Australian Cystic Fibrosis Data Registry 2003. http://staging. cysticfibrosis.sitepoint.com.au/projects/dataregistry/ Date last updated: 2005. Date last accessed: June 10, 2007.